PHARMACEUTICAL ASSESSMENT OF GYNAECOLOGICAL POWDERS WITH THE ADDITION OF HYDROPHILISING SUBSTANCES CONTAINING LACTIC ACID COMPLEXED WITH CHITOSAN

• Authors: Katarzyna Małolepsza-Jarmołowska
• Languages of publication: EN EN

Abstracts

EN

Research on gynaecological preparations followed that of optimising their pharmaceutical properties, which is beneficial for gynaecological powders. Gels obtained from powders containing lactic acid complexed with chitosan revealed a stoichiometric ratio 1:1, 2;1, 3:1, 4:1 and 8:1. Their pH ranged from 3.92 to 4.44 for 1:1 gels and from 2.36 to 2.84 for the 8:1 ratio. The addition of 5% polyethylene glycol-400 increases the pH from 4.52 to 4.92 for 1:1 gels and from 2.54 to 3.41 for the 8:1 ratio. A modification of the composition of the tested powders containing 5% polyethylene glycol-400 increased the range of the dynamic viscosity of formulations suitably from 78 to 520 mPa.s for 1:1 gels and from 39 to 423 mPa.s for the 8:1 ratio. Measurements performed in a biopharmaceutical model revealed that the gels obtained from powders containing lactic acid complexed with chitosan are able to move from 25 to 28 cm.

Keywords

EN

anti-inflammatory drugs; hydrophilic powders passing gels; lactic acid complexed with chitosan; physiological environment of vagina; vaginal infections; vaginal mucosa

Discipline

• PHARMACOLOGY: PHARMACOLOGY

• Publisher: Sieć Badawcza Łukasiewicz - Polskie Towarzystwo Chitynowe
• Journal: Progress on Chemistry and Application of Chitin and its Derivatives
• Year: 2014
• Volume: 19
• Pages: 95-101

Contributors

author

Katarzyna Małolepsza-Jarmołowska

• Chair and Department of Pharmaceutical Technology, Faculty of Pharmacy The “Silesian Piasts” Memorial Medical University of Wroclaw,

References

• 1. Schwebke JR; (2009) New concepts in the aetiology of bacterial vaginosis. Curr. Infect. Dis. Rep. 11, 143 – 147, DOI: 10.1007/s11908-009-0021-7 .
• 2. Brandt M, Abels C, May T, Lohmann K, Schmidts – Winkler I, Hoyme UB; (2008) Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects. Eur. J. Obstet. Gynecol. Reprod. Biol. 141, 158 – 162, DOI: 10.1016/j. ejogrb.2008.07.022.
• 3. Donders GGG, Larson PG, Platz – Christensen JJ, Hallen A, Meijden W, Wölner – Hanssen P; (2009) Variability in diagnosis of clue cells, lactobacillary grading and white blood cells in vaginal wet smears with conventional bright light and phase contrast microscopy. Eur. J. Obstet. Gynecol. Reprod. Biol. 145, 109 – 112, DOI: 10.1016/j.ejogrb.2009.04.012.
• 4. Kubis AA, Małolepsza-Jarmołowska K; (1996) Studies on gynaecological hydrophiling preparations comprising lactic acid. Part 1: Effects of lactic acid and hydrophiling agents on physical and chemical properties of methylcellulose gels. Pharmazie 51, 989 – 990.
• 5. Małolepsza-Jarmołowska K, Kubis AA; (1999) Studies on gynaecological hydrophilic lactic acid preparations. Part 2: Effects of Eudragit® E-100 on properties of methylcellulose gels. Pharmazie 54, 441 – 443.
• 6. Małolepsza-Jarmołowska K, Kubis AA; (2000) Studies on gynaecological hydrophilic lactic acid preparations. Part 3: Effects of chitosan on the properties of methylcellulose gels. Pharmazie 55, 610 – 611.
• 7. Małolepsza-Jarmołowska K, Kubis AA; (2001) Studies on gynaecological hydrophilic lactic acid preparations. Part 4: Effects of polyvinyl pyrrolidone K-90 on properties of methylcellulose gels. Pharmazie 56, 160 – 162.
• 8. Małolepsza-Jarmołowska K, Kubis AA, Hirnle L; (2003) Studies on gynaecological hydrophilic lactic acid preparations. Part 5: The use of Eudragit® E-100 as lactic acid carrier in intravaginal tablets. Pharmazie 58, 260 – 262.
• 9. Małolepsza-Jarmołowska K, Kubis AA, Hirnle L; (2003) Studies on gynaecological hydrophilic lactic acid preparations. Part 6: Use of Eudragit® E-100 as lactic acid carrier in intravaginal tablets. Pharmazie 58, 334 – 336.
• 10. Małolepsza-Jarmołowska K; (2006) Studies on gynaecological hydrophilic lactic acid preparations. Part 7: Use of chitosan as lactic acid carrier in intravaginal tablets (globuli vaginales). Pharmazie 61, 780 – 782.
• 11. Małolepsza-Jarmołowska K; (2007) Studies on gynaecological hydrophilic lactic acid preparations. Part 8: Use of chitosan as lactic acid carrier in intravaginal tablets. Acta Pol. Pharm. 64, 69 – 72.
• 12. Małolepsza-Jarmołowska K; (2010) The effect of poloxamer 407 on the properties of hydrophilic gels containing lactic acid complexed with chitosan. Monograph vol. XV ed. by M. Jaworska “Progress on Chemistry and Application of Chitin and Its Derivatives” 15, 143 – 148.

• Document Type: undetermined